Sanofi gets dengue vax approved in Mexico; Glaxo hit with class action suit over nausea treatment Zofran;

@FiercePharma: Allergy Therapeutics brings long-delayed grass allergy vax into PhII. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI: AbbVie's Imbruvica, Amgen's Kyprolis shine at annual ASH meeting. More | Follow @CarlyHFierce

> On Wednesday, Mexico approved Sanofi's ($SNY) dengue vaccine, the first to treat the mosquito-borne virus. Story

> A class action lawsuit has been filed in Canada against GlaxoSmithKline ($GSK) by women who claim their children were harmed when they received Zofran, a drug they say is commonly prescribed off label for treating nausea during pregnancy. Story

> AstraZeneca's ($AZN) lung cancer treatment Tagrisso has become the fourth med to be made available to U.K. patients before approval under an early access scheme. Report

> Johnson & Johnson's ($JNJ) Janssen has submitted an application to the EMA for use of Stelara in adults with severe active Crohn's disease. Report

Medical Device News

@FierceMedDev: Scientists roll out 3-D printed self-assembling blood vessels. Article | Follow @FierceMedDev

@EmilyWFierce: Pharma ad budgets stay flat, even as spending jumps across the board: Report. FiercePharmaMarketing story | Follow @EmilyWFierce

> Illumina Accelerator discloses its latest funded class of four genomic startups. Story

> Top gynecologists push back at FDA crackdown on power morcellator devices. Report

> Chemotherapy cooling cap to reduce hair loss for breast cancer patients gets FDA nod. Article

Biotech News

@FierceBiotech: Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Eyeing pivotal PhIIIs, Margolin nabs $53M crossover round for Allena. News | Follow @JohnCFierce

@DamianFierce: "You know, at the right price these guys basically will do anything." More from Bloomberg | Follow @DamianFierce

> Rubius goes after genetically re-engineered red-cell drugs with $25M from Flagship. Report

> Cara's oral opioid cuts osteoarthritis pain in a Phase II trial. Story

> Baxalta wins FDA approval with a treatment for a rare bleeding disease. Article

Biotech Research News

> New screening tech at Scripps spotlights diabetes drug candidates. Item

> Dana-Farber researchers highlight progress with new drugs for acute myeloid leukemia. More

> Imperial College scientists engineer a CRISPR/Cas9 breakthrough on malaria. Report

> Florida U team's gene therapy safeguards cognition in rats. Story

> Epilepsy scientific meeting highlights promise of cannabidiol for reducing seizures. Article

Pharma Marketing News

> Can new PhIII data help Gilead's Zydelig stage a comeback in CLL? Article

> Pharma ad budgets stay flat, even as spending jumps across the board: Report. More

> Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera. Story

> Cancer-free President Carter notes Keytruda treatment: Will the celebrity effect kick in? More

> With Paris spotlight on climate change, here's how Big Pharma stacks up. Article

Vaccines News

> Second flu shot helps cancer patients stave off infection, Yale team says. Item

> Japan's Kaketsuken covered up illicit blood product, vaccine production methods for 40 years. More

> Cerberus Capital management invests $105M in PaxVax. Report

> Allergy Therapeutics brings long-delayed grass allergy vax into PhII. Story

> U.S. Army, Hawaii Biotech join for dengue vaccine effort. Article

And Finally... The acute myeloid leukemia (AML) drug market will expand to $932.6 million by 2024 from $342.7 million in 2014, research and consulting firm GlobalData says. More

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.